Whitehawk Therapeutics (NASDAQ:WHWK) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Whitehawk Therapeutics (NASDAQ:WHWK) from a sell rating to a hold rating in a research note published on Saturday.

Several other research analysts have also weighed in on WHWK. Citigroup assumed coverage on shares of Whitehawk Therapeutics in a research note on Thursday, April 16th. They set an “outperform” rating on the stock. B. Riley Financial began coverage on shares of Whitehawk Therapeutics in a report on Thursday, June 25th. They issued a “buy” rating and a $10.00 target price on the stock. Leerink Partners started coverage on shares of Whitehawk Therapeutics in a report on Monday, July 13th. They issued an “outperform” rating and a $9.00 target price on the stock. Oppenheimer reissued an “outperform” rating and set a $7.00 price target on shares of Whitehawk Therapeutics in a research report on Friday, May 8th. Finally, Weiss Ratings lowered shares of Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, June 5th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Whitehawk Therapeutics has an average rating of “Moderate Buy” and an average price target of $8.20.

Whitehawk Therapeutics Trading Up 1.3%

Shares of WHWK opened at $4.76 on Friday. Whitehawk Therapeutics has a 1 year low of $1.57 and a 1 year high of $5.49. The stock has a market cap of $235.38 million, a P/E ratio of -4.25 and a beta of 0.76. The stock’s 50-day moving average price is $4.11 and its two-hundred day moving average price is $3.78.

Whitehawk Therapeutics (NASDAQ:WHWK) last posted its earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.10. As a group, equities analysts forecast that Whitehawk Therapeutics will post -1.37 EPS for the current year.

Institutional Trading of Whitehawk Therapeutics

A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Whitehawk Therapeutics during the second quarter worth about $8,807,000. Deutsche Bank AG acquired a new stake in Whitehawk Therapeutics in the 2nd quarter valued at approximately $145,000. Bank of New York Mellon Corp acquired a new stake in Whitehawk Therapeutics in the 2nd quarter valued at approximately $378,000. Seven Fleet Capital Management LP acquired a new stake in Whitehawk Therapeutics in the 1st quarter valued at approximately $187,000. Finally, Bank of America Corp DE lifted its stake in Whitehawk Therapeutics by 12,761.6% in the 1st quarter. Bank of America Corp DE now owns 52,861 shares of the company’s stock valued at $182,000 after acquiring an additional 52,450 shares in the last quarter. 52.08% of the stock is currently owned by institutional investors.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.